<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref014">
 <label>[14]</label>
 <mixed-citation publication-type="journal">
  <string-name>
   <surname>Maclagan</surname>
   <given-names>LC</given-names>
  </string-name>, 
  <string-name>
   <surname>Visanji</surname>
   <given-names>NP</given-names>
  </string-name>, 
  <string-name>
   <surname>Cheng</surname>
   <given-names>Y</given-names>
  </string-name>, 
  <string-name>
   <surname>Tadrous</surname>
   <given-names>M</given-names>
  </string-name>, 
  <string-name>
   <surname>Lacoste</surname>
   <given-names>AMB</given-names>
  </string-name>, 
  <string-name>
   <surname>Kalia</surname>
   <given-names>L V.</given-names>
  </string-name>, 
  <string-name>
   <surname>Bronskill</surname>
   <given-names>SE</given-names>
  </string-name>, 
  <string-name>
   <surname>Marras</surname>
   <given-names>C</given-names>
  </string-name> (
  <year>2020</year>) 
  <article-title>Identifying drugs with disease-modifying potential in Parkinson’s disease using artificial intelligence and pharmacoepidemiology</article-title>. 
  <source>Pharmacoepidemiol Drug Saf</source>
  <volume>29</volume>, 
  <fpage>864</fpage>–
  <lpage>872</lpage>.
  <pub-id pub-id-type="pmid">32410265</pub-id>
 </mixed-citation>
</ref>
